WARF ADVANCES
Top licensing prospects from the University of Wisconsin-Madison
WT-7695 Achieved 100% Survival at 1 mCi in a Model of Kidney Cancer
UW-Madison researchers have developed a novel compound with best-in-class properties (in vivo tumor uptake, retention and efficacy) for treating CAIX cancers.
Read more
Synthetic Biomolecule Promotes T Cell Proliferation and Tumoricidal Effects
This biological therapeutic – created by fusing the cytokines IL-6 and IL-1β – stimulates the immune system to fight solid tumors.
Read more
Image Analysis of Histologically Normal Prostate Biopsies Predicts Cancer Presence
This simple, rapid and quantitative imaging-based method can be used for the accurate diagnosis and prognosis of prostate cancer.
Read more
Novel Cereblon E3 Ligase Ligands
UW pharmaceutical scientists developed a novel class of molecules that bind cereblon (CRBN), a ubiquitin ligase, and may be used in the development of PROTAC therapeutics.
Read more
Predicting Responses to Disease Treatments
This novel method, called TARGETS (TreAtment Response Generalized Elastic-neT Signatures), predicts optimal treatment responses in oncology patients based on DNA and RNA sequences in circulating tumor cells.
Read more
Automatic In Vitro Diagnostic Medical Device for Intraventricular Drainage
UW-Madison researchers have developed a digitally controlled cerebrospinal fluid (CSF) drainage device for use in ICU settings that provides improved precision and safety.
Read more
Read about more licensing prospects!
Featured UW-Madison Researcher
 |
Mahua Dey, Associate Professor (Tenure) of Neurological Surgery
“We are excited about the work Mahua’s lab is performing. I think everybody understands the importance to treat, and hopefully cure, cancer, particularly debilitating diseases such as malignant brain tumors.” – Rafael Diaz, WARF Licensing Manager |
In the News